Panacea Biotec partners with RDIF to manufacture 100 million doses of Sputnik V in India annually : India has been emerging as the manufacturing hub of the Russian COVID – 19 vaccines, Sputnik V. Stelis Pharma (Strides arm), Hetero, Gland Pharma, and Virchow group are the key manufacturers of the vaccine. These pharma companies have […]
Sputnik V: RDIF to manufacture 100 million doses Read More »
ISSAR pharma licenses its NCEs based on peptide technology in hopes of potential collaborations : ISSAR has been on the lookout for partnering with other companies to get assistance in designing novel peptide–based drugs. It believes that collaborations would allow it to make affordable and accessible drugs for various unmet healthcare needs. In line with
IDT Biologika agrees to produce over 10 million doses of AstraZeneca’s COVID – 19 vaccine : IDT Biologika has recently announced its plan to manufacture around 10 million doses of AstraZeneca’s COVID – 19 vaccine. The German vaccine – maker made this announcement on 16 April 2021 and added that IDT would produce the doses
IDT Biologika agrees to produce Astra’s COVID vaccine Read More »
Third dose of Pfizer’s COVID – 19 vaccine within 12 months of getting fully inoculated could most likely prolong protection : Pfizer’s CEO[1] Albert Bourla has recently made some speculations about Pfizer’s COVID–19 vaccine. He claimed that people might need a 3rd dose of the vaccine after getting fully inoculated. Per his claims, this is
Pfizer announces that it will supply its COVID – 19 vaccine to India only through government contracts : Recently there has been news about the Indian government regarding the procuration of vaccines from foreign companies. This is due to media reports which claim that the government is exploring options to allow private players to do
These articles are contributed by Ms. Ellen D’cunha and edited by PharmaCampus Content Editing Team. About the Author Ellen is a passionate medical content writer and holds her bachelor’s degree in Pharmacy. She is pursuing her master’s in Pharmaceutical Management at IES MCRC Bandra. Her areas of interest include Pharma Brand Management and Digital Marketing.
AstraZeneca’s diabetes drug Farxiga falls short in the global trial conducted to check its efficacy on COVID – 19 patients : On 12 April 2021, AstraZeneca announced the failure of its diabetes drug in treating hospitalized COVID – 19 patients. The drug that was tested using this trial is called Farxiga. The British drugmaker conducted
AstraZeneca yet to respond to EU’s letter on the material breach of contract over the vaccine supply in Europe : On 19 March 2021, EU[1] sent a letter to AstraZeneca to complain over the below–contract supplies of its COVID – 19 vaccine. However, the pharmaceutical company has failed to respond to this letter to date.
Pfizer seeks USFDA’s approval for using its COVID – 19 vaccine in adolescents aged 12 to 15 years old On 9 April 2021, Pfizer – BioNTech sought the USFDA[1] to authorization its COVID – 19 vaccine. This was for the use of the vaccine for 12 to 15 years old in the United States. Pfizer
Pfizer seeks USFDA’s approval for COVID vaccine in adolescents Read More »
Takeda Pharma begins regulatory submissions for its dengue vaccine candidate to EMA : Japan’s Takeda Pharmaceuticals has recently started the regulatory submissions for its dengue vaccine candidate to EMA[1]. This was announced by the company on 25 March 2021. This vaccine is being developed for individuals aged 4 to 60. [4] The drug firm stated
